Doctor-Teen Communication & Antihypertensive Adherence in Chronic Kidney Disease

描述（由申请人提供）：高血压是慢性肾脏病（CKD）进展的最重要的独立风险因素之一。最近完成的ESCAPE试验的结果强调了血压控制作为减缓CKD进展的一种手段的重要性，使抗高血压药物不依从性成为行为干预的主要目标。令人惊讶的是，没有关于患有或不患有CKD的儿童中抗高血压药物依从性的研究。医生与青少年的沟通是促进终身自我管理技能和变化的关键，因为青少年成熟，并承担更多的责任，他/她的照顾。然而，在我们对医生与青少年沟通的一般知识方面，特别是它如何影响养生依从性和健康结果方面，存在着惊人的差距。通过CKD青少年不依从性的全面纵向预测模型，评估已知的风险和弹性因素以及医生与青少年的沟通如何相互作用，是为高危患者制定有效的、有针对性的依从性干预措施的重要前奏。本研究的目的是测试1）青少年抗高血压药物依从性对血压控制和随后CKD进展的影响; 2）医生-青少年沟通对药物依从性随时间推移的影响。这是一项前瞻性研究，纳入了150例接受降压药物治疗的11-19岁CKD（1-5期）青少年。客观测量方法将用于评估抗高血压药物依从性（电子监测和药房续药）、健康结局（例如，动态血压监测和CKD进展的生物标志物），以及医生-青少年沟通（肾脏病学门诊访视的RIAS编码）。此外，将评估已知的不依从风险和弹性因素对医生与青少年沟通和依从性之间关联的调节作用。将在基线、12个月和24个月时测量所有变量;此外，将在6个月、18个月和30个月时测量依从性和健康结局。将使用纵向分析对具有时变协变量的结局变化进行建模。这将使我们能够评估医生与青少年沟通的变化如何影响依从性，以及随后的血压控制和CKD进展。此外，在这项CKD青少年研究中学到的经验教训将增加我们对医生与青少年沟通对慢性病的影响的理解。

DESCRIPTION (provided by applicant): Hypertension is one of the most important independent risk factors for chronic kidney disease (CKD) progression. The results of the recently completed ESCAPE trial highlight the importance of blood pressure control as a means to slow CKD progression, making antihypertensive nonadherence a prime target for behavioral intervention. Surprisingly, there is no research on adherence to antihypertensive medication among children either with or without CKD. Physician-adolescent communication is key for facilitating lifelong self-management skills and changes as the adolescent matures and assumes more responsibility for his/her care. However, there is a striking gap in our knowledge of physician-adolescent communication in general and specifically how it impacts regimen adherence and health outcomes. Evaluating how known risk and resilience factors and physician-adolescent communication interact through a comprehensive, longitudinal predictive model of adolescent nonadherence in CKD is an essential prelude to the development of effective, targeted adherence interventions for high-risk patients. The purpose of this study is to test 1) the impact of antihypertensive medication adherence in adolescents on blood pressure control and subsequent progression of CKD; and 2) the influence of physician-adolescent communication on medication adherence over time. This is a prospective study of 150 adolescents age 11-19 years old with CKD (Stages 1-5) who are prescribed an antihypertensive medication. Objective measurement approaches will be used to assess antihypertensive medication adherence (electronic monitoring and pharmacy refills), health outcomes (e.g., ambulatory blood pressure monitoring and biomarkers of CKD progression), and physician-adolescent communication (RIAS coding of nephrology clinic visits). Additionally, the moderating effect of known nonadherence risk and resilience factors on the association between physician-adolescent communication and adherence will be assessed. All variables will be measured at baseline, 12- and 24- months; additionally, adherence and health outcomes will be measured at 6-, 18- and 30-months. Longitudinal analyses will be used to model the change in outcomes with time-varying covariates. This will allow us to evaluate how changes in physician-adolescent communication impact adherence and then subsequent blood pressure control and CKD progression. Further, the lessons learned in this study of adolescents with CKD will add to our understanding of the impact of physician-adolescent communication across chronic illnesses.